| A Pan-Cancer Patient-Derived Xenograft Histology Image Repository with Genomic and Pathologic Annotations Enables Deep Learning Analysis BS White, XY Woo, S Koc, T Sheridan, SB Neuhauser, S Wang, YA Evrard, ... Cancer Research 84 (13), 2060-2072, 2024 | | 2024 |
| Recommendations for the use of next-generation sequencing (NGS) for patients with advanced cancer in 2024: a report from the ESMO Precision Medicine Working Group MF Mosele, CB Westphalen, A Stenzinger, F Barlesi, A Bayle, I Bièche, ... Annals of Oncology 35 (7), 588-606, 2024 | 1 | 2024 |
| Clinical and genomic landscape of RAS mutations in gynecologic cancers J Son, Y Zhang, H Lin, O Mirallas, P Alvarez Ballesteros, M Nardo, ... Clinical Cancer Research, OF1-OF10, 2024 | | 2024 |
| Plain language summary of the FOENIX-CCA2 study: futibatinib for people with advanced bile duct cancer L Goyal, F Meric-Bernstam, A Hollebecque, JW Valle, C Morizane, ... Future Oncology, 1-12, 2024 | | 2024 |
| Cyclin E1/CDK2 Activation Defines a Key Vulnerability to WEE1 Kinase Inhibition in Gynecological Cancers J Ma, D Kim, H Chung, W Liu, K Jeong, T Ozmen, F Ozmen, M Rames, ... | | 2024 |
| A phase I study of TAK-659 and paclitaxel in patients with taxane-refractory advanced solid tumors MA Gouda, J Shunyakova, A Naing, E Dumbrava, DS Hong, Y Yuan, ... ESMO Open, 103486, 2024 | | 2024 |
| Trastuzumab deruxtecan (T-DXd) in patients (pts) with HER2-expressing head and neck tumors: Outcomes from DESTINY-PanTumor02 (DP-02). F Meric-Bernstam, ST Kim, N Parinyanitikul, A Moreno, CC Lin, ... Journal of Clinical Oncology 42 (16_suppl), 6037-6037, 2024 | | 2024 |
| Telehealth consultations and recruitment trends in clinical trials: A retrospective analysis at investigational cancer therapeutics, a dedicated phase I department at The … C Torrado, A Brink, MA Gouda, L Kang, J Osburn, CJ Patterson, S Charles, ... Journal of Clinical Oncology 42 (16_suppl), 1635-1635, 2024 | | 2024 |
| Recurrence score gene axes scores and outcomes by race and ethnicity in the RxPONDER trial. Y Abdou, JR Hoag, WE Barlow, JR Gralow, F Meric-Bernstam, KS Albain, ... Journal of Clinical Oncology 42 (16_suppl), 515-515, 2024 | | 2024 |
| A phase 1b, multicenter, open-label study of valemetostat in combination with DXd antibody drug conjugates (ADCs), trastuzumab deruxtecan (T-DXd) or datopotamab deruxtecan … J Sands, SM Tolaney, NT Ueno, AI Spira, N Yamamoto, YY Janjigian, ... Journal of Clinical Oncology 42 (16_suppl), TPS4180-TPS4180, 2024 | | 2024 |
| Analysis of drug-related interstitial lung disease (ILD) inpatients (pts) treated with datopotamab deruxtecan (Dato-DXd). J Sands, A Lisberg, A Bardia, T Shimizu, MJ Ahn, LG Paz-Ares, ... Journal of Clinical Oncology 42 (16_suppl), 8623-8623, 2024 | | 2024 |
| A phase 1, first-in-human study of CUSP06, a cadherin-6 (CDH6)-directed antibody-drug conjugate, in patients with platinum-refractory/resistant ovarian cancer and other … AI Spira, EK Lee, RE O'Cearbhaill, P LoRusso, GS Falchook, MR Patel, ... Journal of Clinical Oncology 42 (16_suppl), TPS3166-TPS3166, 2024 | | 2024 |
| Phase I/II study of TROP2 CAR engineered IL15-transduced cord blood-derived NK cells delivered intraperitoneally for the management of platinum resistant ovarian cancer … A Knisely, H Rafei, R Basar, PP Banerjee, Z Metwalli, K Lito, BM Fellman, ... Journal of Clinical Oncology 42 (16_suppl), TPS5626-TPS5626, 2024 | | 2024 |
| Correlation of serum anti-Müllerian hormone (AMH) levels on identification of premenopausal patients (pts) with hormone receptor positive (HR+), HER2-negative, node-positive … K Kalinsky, WE Barlow, HB Pathak, JR Gralow, KS Albain, DF Hayes, ... Journal of Clinical Oncology 42 (16_suppl), 505-505, 2024 | | 2024 |
| Patient-reported symptom interference with activity-and mood-related functioning prior to start of an early-phase oncology combination trial including immune checkpoint blockade. GC George, SA Piha-Paul, EE Dumbrava, V Subbiah, S Fu, ... Journal of Clinical Oncology 42 (16_suppl), 12084-12084, 2024 | | 2024 |
| Response to RAF/MEK/ERK inhibitors in patients with RAS altered and wild-type tumors. MA Gouda, HY Lin, L Kang, H Le, EE Dumbrava, S Fu, DD Karp, ... Journal of Clinical Oncology 42 (16_suppl), 3099-3099, 2024 | | 2024 |
| A phase 1 study of the BET inhibitor ZEN003694 in combination with the MEK1/2 inhibitor binimetinib in solid tumors with RAS pathway alterations and triple-negative breast … C Torrado, K Rai, M Moawad, EE Dumbrava, S Fu, DS Hong, DD Karp, ... Journal of Clinical Oncology 42 (16_suppl), TPS3182-TPS3182, 2024 | | 2024 |
| Results of IMPACT 2, a randomized study evaluating molecular profiling and targeted agents in metastatic cancer at MD Anderson Cancer Center. AM Tsimberidou, S Fu, DS Hong, SA Piha-Paul, A Naing, J Rodon Ahnert, ... Journal of Clinical Oncology 42 (16_suppl), 3153-3153, 2024 | | 2024 |
| Pertuzumab plus trastuzumab (P+T) in patients (pts) with solid tumors with ERBB2or ERBB3amplification (amp) or mutations (mut): Results from the Targeted … EG Dib, M Rothe, PK Mangat, E Garrett-Mayer, E Ahn, AS Alva, N Hafez, ... Journal of Clinical Oncology 42 (16_suppl), 3142-3142, 2024 | | 2024 |
| The multiomic tumor microenvironment landscape of invasive lobular carcinoma of the breast. JA Mouabbi, F Meric-Bernstam, A Nasrazadani, BE Nelson, B Salem, ... Journal of Clinical Oncology 42 (16_suppl), 1044-1044, 2024 | | 2024 |
